SOPHiA GENETICS
SOPHiA GENETICS
SOPHiA GENETICS is the creator of a global data-sharing network – we work with customers from over 750 institutions in over 70 countries. Our network advances data-driven medicine to improve health outcomes and economics worldwide.
Website
https://www.sophiagenetics.com/
Entry
2015
What do we do?
We offer a cloud-based Software-as-a-Service platform — the SOPHiA DDM™ platform — that enables healthcare institutions to get quick, robust insights from their data. We apply our technology to diseases such as cancer and inherited disorders, where combining genomic and phenotypic information is vital to support discoveries, treatment decisions, and drug development efforts.
"When founding SOPHiA GENETICS, our goal was to create a tech company whose impact would significantly improve patients’ care. We’ve worked hard to develop a strong entrepreneurial spirit at SOPHiA GENETICS, encouraging every employee to make a difference. Our corporate DNA, rooted in quality, precision, and robustness, is the key to our success and a promise of hope for millions worldwide."
– Dr. Jurgi Camblong , CEO SOPHiA GENETICS
SOPHiA GENETICS’ dream
SOPHiA GENETICS’ mission is to build the future of AI-assisted medicine. We are integrating multimodal healthcare-omics data, unlocking the existing data silos and developing machine learning models to produce actionable insights that could eventually support healthcare professionals to improve patient outcomes.
MORE INVESTMENTS
Alychlo invests directly in companies, makes select fund investments and manages a long-term small- and mid-cap equities portfolio.
